Tissue resident regulatory T cells: Novel therapeutic targets for human disease

Cellular and Molecular Immunology

Volumn 12, Issue 5, 2015, Pages 543-552

  Zhou, Xiaohui ^a,b   Tang, Jiayou ^a   Cao, Hao ^a   Fan, Huimin ^a,b   Li, Bin ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Research Center   (China)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Areg; Bone; Muscle Repair; Regulatory T cells; Skin memory Tregs; Tissue Tregs; Tumor; VAT Tregs

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3;

BONE; BONE METABOLISM; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MUSCLE REGENERATION; NONHUMAN; OBESITY; REGULATORY T LYMPHOCYTE; REVIEW; SKELETAL MUSCLE; SKIN; TISSUE SPECIFICITY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR VASCULARIZATION; ANTIBODY SPECIFICITY; DISEASES; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; VASCULARIZATION;

DISEASE; HUMANS; INSULIN RESISTANCE; MOLECULAR TARGETED THERAPY; NEOPLASMS; OBESITY; ORGAN SPECIFICITY; T-LYMPHOCYTES, REGULATORY;

EID: 84941084485     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.23     Document Type: Review

References (101)

1. Abbas, A.K., C. Benoist, J.A. Bluestone, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013; 14: 307-8.
2. Zhou, X., S. Bailey-Bucktrout, L.T. Jeker, and J.A. Bluestone. Plasticity of CD4(1) FoxP3(1) T cells. Curr Opin Immunol 2009; 21: 281-5.
3. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
4. Baecher-Allan, C., J.A. Brown, G.J. Freeman, and D.A. Hafler. CD41CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
5. Ng, W.F., P.J. Duggan, F. Ponchel, et al. Human CD4(1)CD25(1) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736-44.
6. Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A.H. Enk. Identification and functional characterization of human CD4(1)CD25(1) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-94.
7. Dieckmann, D., H. Plottner, S. Berchtold, T. Berger, and G. Schuler. Ex vivo isolation and characterization of CD4(1)CD25(1) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
8. Hori, S., T. Nomura, and S. Sakaguchi. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
9. Walker, M.R., D.J. Kasprowicz, V.H. Gersuk, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD41CD252 T cells. J Clin Invest 2003; 112: 1437-43.
10. Sakaguchi, S., M. Miyara, C.M. Costantino, and D.A. Hafler. FOXP31 regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
11. Liu, W., A.L. Putnam, Z. Xu-Yu, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD41 T reg cells. J Exp Med 2006; 203: 1701-11.
12. de Vries, I.J, C. Castelli, C. Huygens, et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2011; 17: 841-8.
13. Medzhitov R. E.M. Shevach G. Trinchieri et al. Highlights of years of immunology in Nature Reviews Immunology. Nat Rev Immunol 2011; 11: 693-702.
14. Korn, T., E. Bettelli, M. Oukka, and V.K. Kuchroo. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
15. Haas, J., B. Fritzsching, P. Trubswetter, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007; 179: 1322-30.
16. Horwitz, D.A., S.G. Zheng, J. Wang, and J.D. Gray. Critical role of IL-and TGF-beta in generation, function and stabilization of Foxp31CD41 Treg. Eur J Immunol 2008; 38: 912-5.
17. Xie, J.J., J. Wang, T.T. Tang, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(2/2) mice. Cytokine 2010; 49: 185-93.
18. Yang, X.O., R. Nurieva, G.J. Martinez, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44-56.
19. Xu, L., A. Kitani, I. Fuss, and W. Strober. Cutting edge: regulatory T cells induce CD41CD252Foxp32 T cells or are selfinduced to become Th17 cells in the absence of exogenous TGFbeta. J Immunol 2007; 178: 6725-9.
20. Zhou, X., N. Kong, J. Wang, et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010; 185: 2675-9.
21. Lu, L., Q. Lan, Z. Li, et al. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A 2010; 111: E3432-40.
22. Vignali , D.A., L.W. Coll ison, and C.J. Workman. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-32.
23. Deaglio, S., K.M. Dwyer, W. Gao, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-65.
24. Facciabene, A., X. Peng, I.S. Hagemann, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-30.
25. Cipolletta, D., M. Feuerer, A. Li, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486: 549-53.
26. Burzyn, D., W. Kuswanto, D. Kolodin, et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155: 1282-95.
27. Huber, S., N. Gagliani, E. Esplugues, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(2) and Foxp31 regulatory CD41 T cells in an interleukin-10-dependent manner. Immunity 2011; 34: 554-65.
28. Cao, X., S.F. Cai, T.A. Fehniger, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-46.
29. Pandiyan, P., L. Zheng, S. Ishihara, J. Reed, and M.J. Lenardo. CD41CD251Foxp31 regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD41 T cells. Nat Immunol 2007; 8: 1353-62.
30. Pere, H., C. Tanchot, J. Bayry, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1: 326-333.
31. Wing, K., Y. Onishi, P. Prieto-Martin, et al. CTLA-4 control over Foxp31 regulatory T cell function. Science 2008; 322: 271-5.
32. Zaiss, M.M., B. Frey, A. Hess, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010; 184: 7238-46.
33. Cipolletta, D., D. Kolodin, C. Benoist, and D. Mathis. Tissular T(regs): a unique population of adipose-tissue-resident Foxp31CD41 T cells that impacts organismal metabolism. Semin Immunol 2011; 23: 431-7.
34. Feuerer, M., L. Herrero, D. Cipolletta, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-9.
35. Chen, Z., A.E. Herman, M. Matos, D. Mathis, and C. Benoist. Where CD41CD251 T reg cells impinge on autoimmune diabetes. J Exp Med 2005; 202: 1387-97.
36. Nguyen, L.T., J. Jacobs, D. Mathis, and C. Benoist. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum 2007; 56: 509-20.
37. Sather, B.D., P. Treuting, N. Perdue, et al. Altering the distribution of Foxp3(1) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007; 204: 1335-47.
38. Tilburgs, T., D.L. Roelen, B.J. van der Mast, et al. Evidence for a selective migration of fetus-specific CD41CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol 2008; 180: 5737-45.
39. Feuerer, M., Y. Shen, D.R. Littman, C. Benoist, and D. Mathis. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009; 31: 654-64.
40. Tanchot, C., M. Terme, H. Pere, et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron 2013; 6: 147-57.
41. Rosenblum, M.D., I.K. Gratz, J.S. Paw, K. Lee, A. Marshak-Rothstein, and A.K. Abbas. Response to self antigen imprints regulatory memory in tissues. Nature 2012; 480: 538-42.
42. Lumeng, C.N. and A.R. Saltiel. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-7.
43. Chen, X., Y. Wu, and L. Wang. Fat-resident Tregs: an emerging guard protecting from obesity-associated metabolic disorders. Obes Rev 2013; 14: 568-78.
44. Winer, S., Y. Chan, G. Paltser, et al. Normalization of obesityassociated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-9.
45. Eller, K., A. Kirsch, A.M. Wolf, et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011; 60: 2954-62.
46. Tontonoz, P., L. Nagy, J.G. Alvarez, V.A. Thomazy, and R.M. Evans. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
47. Zeng, H. and H. Chi. Metabolic control of regulatory T cell development and function. Trends Immunol 2015; 36: 3-12.
48. Furusawa, Y., Y. Obata, S. Fukuda, et al. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
49. Arpaia, N., C. Campbell, X. Fan, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5.
50. Smith, P.M., M.R. Howitt, N. Panikov, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-73.
51. Michalek, R.D., V.A. Gerriets, S.R. Jacobs, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD41 T cell subsets. J Immunol 2011; 186: 3299-303.
52. Sugii, S., P. Olson, D.D. Sears, et al. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A 2009; 106: 22504-9.
53. Pettersson, U.S, T.B. Walden, P.O. Carlsson, L. Jansson, and M. Phillipson. Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. PLoS One 2012; 7: e46057.
54. Ilan, Y., R. Maron, A.M. Tukpah, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A 2010; 107: 9765-70.
55. Osborn, O. and J.M. Olefsky. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-74.
56. Svec, P., B. Vasarhelyi, B. Paszthy, et al. Do regulatory T cells contribute to Th1 skewness in obesity? Exp Clin Endocrinol Diabetes 2007; 115: 439-43.
57. Beyer, M., Y. Thabet, R.U. Muller, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol 2011; 12: 898-907.
58. Bending, D., A.M. Pesenacker, S. Ursu, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol 2014; 193: 2699-708.
59. Villalta, S.A., W. Rosenthal, L. Martinez, et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med 2014; 6: 258ra142.
60. Tidball, J.G. and S.A. Villalta. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173-87.
61. Tiemessen, M.M., A.L. Jagger, H.G. Evans, M.J. van Herwijnen, S. John, and L.S. Taams. CD41CD251Foxp31 regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 2007; 104: 19446-51.
62. Weirather, J., U.D. Hofmann, N. Beyersdorf, et al. Foxp31 CD41 T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res 2014; 115: 55-67.
63. Goldring, K., T. Partridge, and D. Watt. Muscle stem cells. J Pathol 2002; 197: 457-67.
64. Shao, J. and H. Sheng. Amphiregulin promotes intestinal epithelial regeneration: roles of intestinal subepithelial myofibroblasts. Endocrinology 2010; 151: 3728-37.
65. Monticelli, L.A., G.F. Sonnenberg, M.C. Abt, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12: 1045-54.
66. Golding, J.P., E. Calderbank, T.A. Partridge, and J.R. Beauchamp. Skeletal muscle stem cells express anti-apoptotic ErbB receptors during activation from quiescence. Exp Cell Res 2007; 313: 341-56.
67. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
68. Curiel, T.J., G. Coukos, L. Zou, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
69. Nagaraj, S., K. Gupta, V. Pisarev, et al. Altered recognition of antigen is a mechanism of CD81 T cell tolerance in cancer. Nat Med 2007; 13: 828-35.
70. Dolcetti, L., I. Marigo, B. Mantelli, E. Peranzoni, P. Zanovello, and V. Bronte. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267: 216-25.
71. Facciabene, A., G.T. Motz, and G. Coukos. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72: 2162-71.
72. Zhang, L . , J.R. Conejo-Garcia, D. Katsaros, et al . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13.
73. Hanahan, D. and R.A. Weinberg. The hallmarks of cancer. Cell 2000; 100: 57-70.
74. Dirkx, A.E., M.G. Oude Egbrink, M.J. Kuijpers, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-9.
75. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
76. Hamzah, J., M. Jugold, F. Kiessling, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008; 453: 410-4.
77. Bao, S., Q. Wu, S. Sathornsumetee, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-8.
78. Manning, E.A., J.G. Ullman, J.M. Leatherman, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13: 3951-9.
79. Shrimali, R.K., Z. Yu, M.R. Theoret, D. Chinnasamy, N.P. Restifo, and S.A. Rosenberg. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-80.
80. Huang, Y., J. Yuan, E. Righi, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109: 17561-6.
81. Pearlman, J.D., M.G. Hibberd, M.L. Chuang, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1995; 1: 1085-9.
82. Wada, J., H. Suzuki, R. Fuchino, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 2009; 29: 881-8.
83. Gupta, S., K. Joshi, J.D. Wig, and S.K. Arora. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 2007; 46: 792-7.
84. Giatromanolaki, A., G.J. Bates, M.I. Koukourakis, et al. The presence of tumor-infiltrating FOXP31 lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008; 110: 216-21.
85. Casares, N., L. Arribillaga, P. Sarobe, et al. CD41/CD251regulatory cells inhibit activation of tumor-primed CD41 T cells with IFNgamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003; 171: 5931-9.
86. Zhan, H.L., X. Gao, X.F. Zhou, X.Y. Pu, and D.J. Wang. Presence of tumour-infiltrating FOXP31 lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas. Asian Pac J Cancer Prev 2012; 13: 867-72.
87. Zhou, X., B. Li, H. Fan, and Z. Liu. Control of regulatory T cells and T helper cells in human diseases: from bench to bedside. J Mol Cell Biol 2013; 5: 210-1.
88. Schmitt, F., P. Govindaswamy, G. Suss-Fink, et al. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem 2008; 51: 1811-6.
89. Abe, F., I. Younos, S. Westphal, et al. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Int Immunopharmacol 2010; 10: 140-5.
90. Adotevi, O., H. Pere, P. Ravel, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991-8.
91. Zaiss, M.M., K. Sarter, A. Hess, et al. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum 2010; 62: 2328-38.
92. Mahnke, K., T. Bedke, and A.H. Enk. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007; 250: 1-13.
93. Hilchey, S.P. and S.H. Bernstein. Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD41and CD81T-cell proliferation within unseparated mononuclear cells from malignant and nonmalignant human lymph node biopsies. Immunol Invest 2007; 36: 629-48.
94. Kong, N., Q. Lan, M. Chen, et al. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis 2012; 71: 1567-72.
95. Pasparakis, M., I. Haase, and F.O. Nestle. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014; 14: 289-301.
96. Gebhardt, T., L.M. Wakim, L. Eidsmo, P.C. Reading, W.R. Heath, and F.R. Carbone. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009; 10: 524-30.
97. Rosenblum, M.D., I.K. Gratz, J.S. Paw, K. Lee, A. Marshak-Rothstein, and A.K. Abbas. Response to sel f antigen imprints regulatory memory in tissues. Nature 2011; 480: 538-42.
98. Graham, J.B., A. Da Costa, and J.M. Lund. Regulatory T cells shape the resident memory T cell response to virus infection in the tissues. J Immunol 2013; 192: 683-90.
99. Sanchez Rodriguez, R, M.L. Pauli, I.M. Neuhaus, et al. Memory regulatory T cells reside in human skin. J Clin Invest 2014; 124: 1027-36.
100. Wiig, H., A. Schroder, W. Neuhofer, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest 2013; 123: 2803-15.
101. Petukhova, L., M. Duvic, M. Hordinsky, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466: 113-7.